US FDA approves Verona Pharma’s therapy for ‘smoker’s lungs’
(Reuters) – The U.S. Food and Drug Administration has granted approval for a treatment from Verona Pharma for a chronic lung disease that commonly affects smokers, the U.K.-based company said on Wednesday. The U.S. FDA’s assent for the therapy, to be sold under the brand Ohtuvayre, is the company’s first and provides a new inhaled…